tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Allogene Therapeutics Advances in CAR T Cell Therapy
PremiumCompany AnnouncementsAllogene Therapeutics Advances in CAR T Cell Therapy
1M ago
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
Premium
The Fly
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
1M ago
Allogene Therapeutics options imply 16.7% move in share price post-earnings
Premium
The Fly
Allogene Therapeutics options imply 16.7% move in share price post-earnings
1M ago
Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyAllogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
2M ago
Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
Premium
The Fly
Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
2M ago
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
Premium
Company Announcements
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
2M ago
Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
PremiumRatingsPromising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
4M ago
Allogene Therapeutics provides updated Phase 1 TRAVERSE study of ALLO-316
Premium
The Fly
Allogene Therapeutics provides updated Phase 1 TRAVERSE study of ALLO-316
4M ago
Allogene Therapeutics’ Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Allogene Therapeutics’ Earnings Call: Progress Amid Challenges
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100